視網膜靜脈阻塞治療市場－全球產業規模、佔有率、趨勢、機會、預測：依疾病類型、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

全球視網膜靜脈阻塞 (RVO) 治療市場預計將從 2025 年的 31.3 億美元成長到 2031 年的 46.8 億美元，複合年成長率為 6.93%。

該市場主要集中在旨在減輕血栓性視網膜阻塞（RVO）患者黃斑部水腫和改善視力的藥物療法，特別是抗血管內皮生長因子（抗VEGF）藥物和皮質類固醇植入物。全球老化以及高血壓、糖尿病和心血管疾病等生活方式相關風​​險因素的日益普遍，是推動市場擴張的根本原因。所有這些因素都會顯著增加視網膜血管事件的發生率。這些全身性健康問題會損害視網膜血管的健康，導致更多患者容易發生此類事件，從而推動了對有效藥物療法的需求，以控制威脅視力的併發症。 Irea HD等關鍵療法的強勁表現證明了這一點，該藥在核准用於治療RVO後，銷售額顯著成長。此外，先進的抗VEGF藥物和皮質類固醇藥物的湧現，以及大量新型生物相似藥的研發，正透過滿足減輕治療負擔的迫切需求，改變市場動態。這些藥物透過延長作用時間，最大限度地減少了侵入性玻璃體內注射的頻率，從而提高了患者的長期依從性。高濃度製劑的快速普及和Vabysmo等創新視網膜療法的積極推廣就證明了這一點。

市場促進因素

文明病（尤其是糖尿病和高血壓）的日益流行，以及全球人口老化，是視網膜靜脈阻塞治療市場的主要促進因素。這些全身性健康問題會顯著損害視網膜血管的健康，增加需要治療性介入的血栓事件的發生率。隨著易患這些血管疾病的患者群體不斷成長，對有效藥物療法的需求也隨之增加，這些藥物療法可以控制諸如黃斑部水腫等威脅視力的併發症。這種臨床需求的激增反映在關鍵療法的財務表現上。根據再生元製藥公司於2025年10月發布的2025年第三季財務業績，Eylea HD在美國的淨銷售額成長了10%，達到4.31億美元，這主要得益於其核准用於治療視網膜靜脈阻塞後銷量和需求的成長。同時，先進的抗VEGF藥物和皮質類固醇藥物的湧現，以及大量新型生物相似藥的研發，正透過滿足減輕治療負擔的迫切需求，改變市場動態。臨床醫師和患者越來越重視能夠提高療效持久性、減少侵入性玻璃體內注射次數並增強長期依從性的新一代藥物。產品採用率數據也印證了這種轉變為高效療法的趨勢。根據拜耳公司於2025年11月發布的2025年第三季財報，新型高濃度阿夫拉維西普製劑迅速獲得市場認可，目前已佔該產品總銷售額的四分之一以上。整體市場動能也進一步推動了競爭格局的轉變。羅氏公司於2025年7月宣布，其雙特異性抗體藥物Vabysmo上半年銷售額成長18%，達到21億瑞士法郎，凸顯了創新視網膜療法的積極擴張。

市場挑戰

然而，長期抗VEGF療法固有的沉重治療負擔正在阻礙市場成長。儘管這些藥物療法能夠改善功能，但頻繁的玻璃體內注射給患者帶來了相當大的後勤和心理負擔，導致注射疲勞、依從性差，最終導致治療中斷。這種嚴格的治療方案通常需要每月或每兩個月去醫院就診，不僅擾亂日常生活，還會為看護者帶來巨大的間接成本。這有效地限制了市場規模，並侵蝕了潛在收入。調查顯示，63%的受訪專家表示，由於治療取得困難或治療負擔過重，他們在2025年放棄了對患者的隨訪，這足以說明患者流失問題的嚴重性。如此高的流失率表明，由於目前給藥方式的繁瑣，導致患者依從性差，這正在直接縮小目標市場規模。

市場趨勢

為此，全球視網膜靜脈阻塞（RVO）治療市場正經歷重大變革，其特徵是向長效抗血管內皮生長因子（VEGF）給藥方案轉變。這主要集中在新型抗體-生物聚合物偶聯物的研發上，旨在更長時間地維持治療有效的眼內藥物濃度，從而實現每年兩次給藥，且不影響視功能改善，例如talocimab tedromer等藥物的研究數據就證明了這一點。同時，具成本效益的抗VEGF生物相似藥的市場滲透正在從根本上改變視網膜治療的經濟結構，打破品牌生技藥品的價格壟斷。隨著傳統抗VEGF製劑的專利到期，醫療系統正積極引入替代生物相似藥以控制不斷飆升的成本，而銷售量的成長反映了這些經濟永續且臨床療效相當的替代藥物在臨床實踐中的廣泛認可。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：視網膜靜脈阻塞治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 疾病類型（中心性視網膜靜脈阻塞（CRVO）、分支性視網膜靜脈阻塞（BRVO））
  • 治療方法（抗血管內皮生長因子（抗VEGF）、皮質類固醇、其他）
  • 依最終用戶（醫院/診所、零售藥局、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美視網膜靜脈阻塞治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲視網膜靜脈阻塞治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區視網膜靜脈阻塞治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲視網膜靜脈阻塞治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲視網膜靜脈阻塞治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球視網膜靜脈阻塞治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Retinal Vein Occlusion (RVO) Treatment Market is projected to experience robust growth, escalating from USD 3.13 billion in 2025 to USD 4.68 billion by 2031, at a compound annual growth rate of 6.93%. This market primarily encompasses pharmacotherapies, notably anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroid implants, designed to mitigate macular edema and enhance visual acuity in patients afflicted by thrombotic retinal blockages. The market's expansion is fundamentally propelled by a globally aging population and the increasing prevalence of lifestyle-related risk factors such as hypertension, diabetes mellitus, and cardiovascular disorders, all of which significantly elevate the incidence of retinal vascular events. These systemic health issues compromise retinal vascular integrity, thereby increasing the patient pool susceptible to such events and consequently driving demand for effective pharmacotherapies to manage vision-threatening complications; this is evident in the strong financial performance of leading therapeutics like Eylea HD, which saw significant sales increases following its RVO approval. Additionally, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden through extended durability, which minimizes the frequency of invasive intravitreal injections and improves long-term compliance, as demonstrated by the rapid uptake of high-strength formulations and the aggressive expansion of innovative retinal therapies such as Vabysmo.

Market Driver

The escalating prevalence of lifestyle-related comorbidities, particularly diabetes and hypertension, alongside an expanding global geriatric population, stands as a primary catalyst for the retinal vein occlusion treatment market. These systemic health issues significantly compromise retinal vascular integrity, leading to a higher incidence of thrombotic events that necessitate therapeutic intervention. As the patient pool susceptible to these vascular disorders grows, there is a consequential rise in the demand for effective pharmacotherapies to manage vision-threatening complications like macular edema. This surge in clinical demand is reflected in the financial performance of leading therapeutics; according to Regeneron Pharmaceuticals, October 2025, in the 'Third Quarter 2025 Financial and Operating Results', U.S. net sales of Eylea HD increased 10% to $431 million, driven by higher sales volumes and rising demand following its approval for retinal vein occlusion. Simultaneously, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden. Clinicians and patients are increasingly prioritizing next-generation agents that offer extended durability, thereby reducing the frequency of invasive intravitreal injections and improving long-term compliance. This transition toward higher-efficacy treatments is evident in product uptake data; according to Bayer, November 2025, in the 'Third Quarter 2025 Financial Report', the new high-strength formulation of aflibercept has rapidly gained traction, now accounting for more than a quarter of the product's total sales mix. This competitive shift is further underscored by the broader market momentum, where according to Roche, July 2025, sales of the bispecific antibody Vabysmo surged 18% to CHF 2.1 billion in the first half of the year, highlighting the aggressive expansion of the innovative retinal therapy segment.

Market Challenge

However, the market's growth faces a significant impediment due to the substantial treatment burden inherent in chronic anti-VEGF therapy. While these pharmacotherapies offer functional improvements, the necessity for frequent intravitreal injections creates considerable logistical and psychological strain on patients, leading to injection fatigue, non-compliance, and, ultimately, treatment discontinuation. This rigorous regimen, often requiring monthly or bimonthly clinical visits, disrupts daily life and incurs significant indirect costs for caregivers, effectively acting as a ceiling on market volume and eroding potential revenue. The severity of this attrition is highlighted by reports that 63% of surveyed specialists experienced patient loss to follow-up in 2025 due to treatment access and burden challenges. Such high rates of drop-out demonstrate how non-compliance, driven by the demanding nature of current delivery methods, directly erodes the addressable market size.

Market Trends

In response, the Global RVO Treatment Market is undergoing a pivotal transformation marked by a shift toward extended-duration anti-VEGF dosing regimens, focusing on developing novel antibody biopolymer conjugates designed to maintain therapeutic intraocular concentrations for much longer periods, thereby enabling biannual dosing without compromising visual gains, as exemplified by positive data from studies on agents like tarcocimab tedromer. Concurrently, the market penetration of cost-effective anti-VEGF biosimilars is fundamentally reshaping the economic landscape of retinal care by dismantling the pricing monopoly of branded biologics. As patents for legacy anti-VEGF agents expire, healthcare systems are aggressively integrating interchangeable biosimilars to manage escalating costs, with strong commercial volume reflecting a robust acceptance of these fiscally sustainable and clinically equivalent alternatives in practice.

Key Market Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

Report Scope

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Vein Occlusion Treatment Market, By Disease Type

• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion Treatment Market, By Treatment

• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

Retinal Vein Occlusion Treatment Market, By End-user

• Hospital & Clinics
• Retail Pharmacy
• Others

Retinal Vein Occlusion Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.

Available Customizations:

Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Retinal Vein Occlusion Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
  • 5.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
  • 5.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Retinal Vein Occlusion Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-user
  • 6.3.2. Canada Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-user
  • 6.3.3. Mexico Retinal Vein Occlusion Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-user

7. Europe Retinal Vein Occlusion Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-user
  • 7.3.2. France Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-user
  • 7.3.3. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-user
  • 7.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End-user
  • 7.3.5. Spain Retinal Vein Occlusion Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End-user

8. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-user
  • 8.3.2. India Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-user
  • 8.3.3. Japan Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-user
  • 8.3.4. South Korea Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End-user
  • 8.3.5. Australia Retinal Vein Occlusion Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End-user

9. Middle East & Africa Retinal Vein Occlusion Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-user
  • 9.3.2. UAE Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-user
  • 9.3.3. South Africa Retinal Vein Occlusion Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-user

10. South America Retinal Vein Occlusion Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment
  • 10.2.3. By End-user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End-user
  • 10.3.2. Colombia Retinal Vein Occlusion Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End-user
  • 10.3.3. Argentina Retinal Vein Occlusion Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Regeneron Pharmaceuticals Inc.
• 15.4. Taiwan Liposome Company, Ltd.
• 15.5. Aerie Pharmaceuticals Inc.
• 15.6. CalciMedica Inc.
• 15.7. Outlook Therapeutics, Inc.
• 15.8. Kodiak Sciences Inc.
• 15.9. Chugai Pharmaceutical Co., Ltd.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer